GSA Capital Partners LLP Purchases New Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

GSA Capital Partners LLP acquired a new position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 9,886 shares of the company’s stock, valued at approximately $277,000.

Other large investors also recently added to or reduced their stakes in the company. State of Wyoming bought a new position in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after acquiring an additional 994 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at $129,000. Finally, Envestnet Asset Management Inc. acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $221,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of analyst reports. Citizens Jmp decreased their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research note on Friday. Stifel Nicolaus boosted their target price on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. lifted their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.50.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $62.98 on Friday. The business’s 50-day simple moving average is $75.41 and its 200-day simple moving average is $46.54. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The stock has a market capitalization of $4.45 billion, a PE ratio of -79.72 and a beta of -2.06.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.